One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach?

Multiparametric magnetic resonance imaging (mpMRI) is the standard for local prostate cancer (PCa) staging. Whole‐body MRI (wbMRI) has shown capabilities for metastatic screening. This study assesses the feasibility and value of an all‐in‐one AJCC TNM staging of PCa during a unique MRI session combining mpMRI and wbMRI.

[1]  J Alfred Witjes,et al.  Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. , 2005, Radiology.

[2]  C. Kim,et al.  Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. , 2010, AJR. American journal of roentgenology.

[3]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[4]  B. Carey,et al.  Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.

[5]  R. Eeles,et al.  Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer , 2009, Journal of medical imaging and radiation oncology.

[6]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[7]  M. Graefen,et al.  External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection , 2013, The Prostate.

[8]  Jelle O. Barentsz,et al.  Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis , 2002, European Radiology.

[9]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[10]  J. Catto,et al.  Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost? , 2012, European urology.

[11]  M. Harisinghani,et al.  Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer , 2013, BJU international.

[12]  P. Therasse,et al.  Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases , 2005, The Prostate.

[13]  B. Tombal,et al.  Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa) , 2010, European Radiology.

[14]  B. Bloch,et al.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI , 2012, European Radiology.

[15]  J. Babb,et al.  Diffusion‐weighted imaging of the abdomen at 3.0 Tesla: Image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla , 2011, Journal of magnetic resonance imaging : JMRI.

[16]  Aytekin Oto,et al.  Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. , 2013, Radiology.

[17]  M. Zelefsky,et al.  High-risk prostate cancer: from definition to contemporary management. , 2012, European urology.

[18]  F. Saad,et al.  Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer , 2008, Cancer.

[19]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[20]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[21]  Tiina Seppälä,et al.  Commissioning of MRI‐only based treatment planning procedure for external beam radiotherapy of prostate , 2013, Magnetic resonance in medicine.

[22]  S. Reske,et al.  Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. , 2012, The Journal of urology.

[23]  F. Mottaghy,et al.  Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. , 2011, European urology.

[24]  P. Therasse,et al.  Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Huda,et al.  Effective doses in radiology and diagnostic nuclear medicine: a catalog. , 2008, Radiology.

[26]  A. Verbaeys,et al.  Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. , 2011, European journal of radiology.

[27]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[28]  Baris Turkbey,et al.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. , 2012, AJR. American journal of roentgenology.

[29]  Robert E Lenkinski,et al.  Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. , 2007, Radiology.

[30]  M McJury,et al.  The influence of MRI scan position on image registration accuracy, target delineation and calculated dose in prostatic radiotherapy. , 2012, The British journal of radiology.

[31]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[32]  B. Tombal,et al.  Novel imaging techniques reshape the landscape in high-risk prostate cancers , 2013, Current opinion in urology.

[33]  N. Lumen,et al.  Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. , 2013, Clinical genitourinary cancer.